Hieronder nog een mooi overzicht uit Linkedin geplaatst door Dave Marver.
Feeds
Organisatiepagina weergeven voor ONWARD Medical, afbeelding
ONWARD Medical
15.750 volgers
2 d Bewerkt
?? Three years ago, we made history with the largest pre-revenue medtech IPO in Europe...ever.
Since then, we’ve been on an incredible journey fueled by a strong team, loyal investors and committed partners. We’ve grown from a promising startup to a company on the brink of commercialization.
As we reflect on the milestones since our Euronext public listing in October 2021, we’re excited to share some of our most notable achievements:
Innovation
? Accrued 278 issued patents, strengthening and protecting our first-mover advantage
? Awarded 10 US FDA Breakthrough Device Designations across our ARC-EX, ARC-IM, and ARC-BCI platforms
Technological
? Completed initial development of the investigational ARC-IM® Neurostimulator, which has been implanted in humans in clinical feasibility studies since May 2022
? Completed initial development of the ARC-IM Lead, which has been implanted in humans in clinical feasibility studies since May 2023
? Completed initial development of the investigational ARC-BCI™ System, which has been implanted in humans in clinical feasibility studies since late 2023
Corporate
? Awarded a grant from our strategic partner, the Christopher & Dana Reeve Foundation, supporting our work using brain-computer interface (BCI) technology
? Completed a 20M Euro capital raise in March 2024, and a financing agreement with Runway Growth Capital in June 2024, providing up to EUR 52.5M in additional capital over the next few years to fund upcoming milestones
? Successfully raised 50M Euro in new funding in October 2024, led by a cornerstone investment from Ottobock, a global leader in prosthetics, orthotics, and exoskeleton technology
? Gained equity research coverage from Stifel Financial Corp., Bryan, Garnier & Co, KBC Securities, Degroof Petercam, and Kepler Cheuvreux
Clinical
? Submitted a De Novo application to the US Food and Drug Administration (FDA) for our investigational ARC-EX® System
? Published results of our Up-LIFT pivotal trial for ARC-EX Therapy in Nature Medicine
? Conducted several clinical feasibility studies for our ARC-IM Therapy, exploring the use of our ARC-IM® System to restore movement and autonomic function after SCI and Parkinson’s disease
? Paired our ARC-IM System with an implanted brain-computer interface (BCI) to enable thought-driven movement
? We are grateful to Euronext and our investors for supporting our goal to serve the SCI community with breakthrough solutions. Your belief in our vision demonstrates the importance of investment to drive innovation. ??